Aberdeen Group
PYXS icon

Aberdeen Group’s Pyxis Oncology PYXS Stock Holding History

Aberdeen Group’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-913,045
Closed -$1M – 976
2025
Q2 		$1M Hold
913,045
– – ﹤0.01% 829
2025
Q1 		$895K Hold
913,045
– – ﹤0.01% 826
2024
Q4 		$1.42M Hold
913,045
– – ﹤0.01% 791
2024
Q3 		$3.35M Buy
913,045
+204,742
+29% +$716K 0.01% 714
2024
Q2 		$2.34M Hold
708,303
– – ﹤0.01% 734
2024
Q1 		$3.02M Hold
708,303
– – 0.01% 737
2023
Q4 		$1.27M Buy
+708,303
New +$1.21M ﹤0.01% 818

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $1.07B AUM 75.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
SC
Stempoint Capital New York $520M AUM 281.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return